Thu, Jul 24, 2014, 5:07 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Neuralstem, Inc. Message Board

  • stockinsight43 stockinsight43 Jul 31, 2013 7:46 AM Flag

    Bottom line, Neuralstem has a cure for ALS in the works.

    No other company in the world is this close to beating ALS. Take a look at all previous attempts and trials from other biotechs. CUR is the only one that's got a cure in flight: "For 700-800 days, human fetal neural stem cells, cultivated by Neuralstem, have substantially slowed muscle degeneration—the hallmark of ALS—in six patients. There has been “no significant disease progression” in these patients, says American Neurological Association president Eva Feldman.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Nice day. Up 14 cents today on average volume. Shorts may be sweating it a bit as any good news should move this up past $1.80 and possibly to $2.

      Sentiment: Strong Buy

    • They only other game in town is someone trying to develope a vaccine for ALS and that is years down the road. There are a bunch of things Neuralstem is doing that is of benefit to the Stem cell science. I believe the delivery platform is also the key here for the ALS, and SC trials.

      • 1 Reply to afjim74
      • IMO, ALS is not even going to be the main application for NSI-566. ALS does seem likely to turn out to be the initial proving ground for NSI-566. CUR was not even going after ALS until Dr. Eva Feldman (an ALS researcher not affiliated with CUR at the time, and never paid by CUR) believed that NSI-566 could be of benefit to ALS patients. NSI-566 has many more potential nerve-related applications, so even an ALS vaccine years down the road (if ever) would not render NSI-566 worthless. And then of course there is NSI-189, which has the potential to dwarf NSI-566 in profitability to CUR.

        Sentiment: Strong Buy

 
CUR
3.25-0.07(-2.11%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.